

C1  
vaccine antigen, the surface antigen having an adjuvant effect on said vaccine antigen. Each vaccine dose includes up to about 1 milligram each of the surface antigen and vaccine antigen. The vaccine formulation may include one or more of the following: a preservative, a stabilizer and a second vaccine antigen. - -

At page 6, please delete the paragraph extending from line 13 to line 16 and replace with the following:

C2  
- - -It is possible to obtain a wider spectrum of immune response generated by HBcAg regarded as an important antigen *per se* in anti-HBV protection. Furthermore, the IgG seric levels anti-HBsAg reached by mucosal inoculation is as intense as the one obtained with the systemic inoculation in alum. - -

In the claims:

14  
Please cancel claims 11-14 and 28-30. Also, please amend claims 15-19 and 21-33; and add new claims 34-37 as follows: (All the pending claims 15-27 and 31-37 are recited below for the Examiner's convenience).

15. (Amended) A vaccine formulation suitable for mucosal administration, comprising:

- C3  
Sub.D37
- (a) a mixture of a first vaccine antigen which is Hepatitis B virus surface antigen (HBsAg), and
  - (b) a second vaccine antigen which is a non-living vaccine antigen comprising an antigen of a viral nucleocapsid;